Viktor Grünwald
维克托·格吕恩瓦尔德
MD
Professor of Medical Oncology; Head, Interdisciplinary GU Oncology肿瘤内科教授；泌尿肿瘤跨学科项目主任
👥Biography 个人简介
Viktor Grünwald, MD is Professor of Medical Oncology and Head of Interdisciplinary Genitourinary Oncology at University Hospital Essen and the West German Cancer Center. He is Germany's most prominent renal cell carcinoma specialist and a leading investigator of targeted therapy and IO-based combinations in advanced kidney cancer. He leads multiple German and European RCC trials and contributes extensively to EAU and ESMO guideline committees.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
IO+TKI Combination Trials in Advanced RCC
Led German and European cooperative group trials investigating IO+TKI combinations including nivolumab-based regimens in advanced RCC, contributing registrational and exploratory data that expanded evidence for combination approaches across risk groups and histologies.
EAU and ESMO RCC Guideline Development
Served on the European Association of Urology and ESMO RCC guideline panels, translating emerging clinical trial data into practical recommendations for European urologists and oncologists managing advanced renal cell carcinoma.
Translational Research on Resistance Mechanisms in RCC
Conducted molecular and biomarker studies characterizing resistance mechanisms to VEGFR TKIs and checkpoint inhibitors in advanced RCC, identifying actionable genomic alterations and immune evasion pathways that may guide future combination strategies.
Representative Works 代表性著作
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma: German Subgroup Analysis of CheckMate 9ER
European Urology Oncology (2022)
German subgroup analysis of CheckMate-9ER confirming consistent efficacy and safety of nivolumab+cabozantinib over sunitinib in the European population, supporting adoption of this combination as a preferred first-line RCC standard in Germany.
EAU Guidelines on Renal Cell Carcinoma 2023
European Urology (2023)
Comprehensive EAU guideline covering localized and metastatic RCC management, incorporating IO+TKI and dual-IO combinations with evidence-based recommendations for European urological oncology practice.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 维克托·格吕恩瓦尔德 的研究动态
Follow Viktor Grünwald's research updates
留下邮箱，当我们发布与 Viktor Grünwald（University Hospital Essen / West German Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment